Atherosclerosis in type 2 diabetes mellitus and insulin resistance: Mechanistic links and therapeutic targets

Journal of Diabetes and its Complications

Volumn 16, Issue 6, 2002, Pages 401-415

  Plutzky, Jorge ^a   Viberti, Giancarlo ^b   Haffner, Steven ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cardiovascular risk; Inflammation; Insulin resistance; Microalbuminuria; Thiazolidinediones

Indexed keywords

ALPHA CHEMOKINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; C REACTIVE PROTEIN; CIGLITAZONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CYTOKINE RELEASE; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIUM LESION; FIBRINOLYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MACROPHAGE ACTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER; THROMBOSIS; ANIMAL; ARTERIOSCLEROSIS; DIABETIC ANGIOPATHY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE;

EID: 0036860896     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(02)00202-7     Document Type: Article

References (159)

1. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Journal of the American Medical Association. 286:2001;64-70.
2. Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dandona P. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? Journal of Clinical Endocrinology and Metabolism. 86:2001;3250-3256.
3. Aljada A., Ghanim H., Assian E., Dandona P. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism. 51:2002;487-491.
4. Aljada A., Saadeh R., Assian E., Ghanim H., Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. Journal of Clinical Endocrinology and Metabolism. 85:2000;2572-2575.
5. Alzaid A.A. Microalbuminuria in patients with NIDDM: an overview. Diabetes Care. 19:1996;79-89.
6. Aubert J., Safonova I., Negrel R., Ailhaud G. Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells. Biochemical and Biophysical Research Communications. 250:1998;77-82.
7. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., Staels B., Auwerx J., Laville M., Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46:1997;1319-1327.
8. Bakogianni M.C., Kalofoutis C.A., Skenderi K.I., Kalofoutis A.T. Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease. Journal of Diabetes and its Complications. 15:2001;265-269.
9. Bakris G., Weston W.M., Rappaport E.B., Freed M.I. Rosiglitazone produces long-term reductions in urinary albumin excretion in type 2 diabetes. Diabetologia. 42(Suppl. 1):1999;A230.
10. Bakris G.L. Microalbuminuria: what is it? Why is it important? What should be done about it? Journal of Clinical Hypertension. 3:2001;99-102.
11. Bakris G.L., Dole J.F., Porter L.E., Huang C., Freed M.I. Rosiglitazone improves blood pressure in patients with type 2 dibetes. Diabetes. 49(Suppl. 1):2000;A96.
12. Banerji M., Lebovitz H.E., Dugbartey M. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus. Diabetes. 50(Suppl. 2):2001;A90.
13. Bell L., Madri J.A. Influence of the angiotensin system on endothelial and smooth muscle cell migration. American Journal of Pathology. 137:1990;7-12.
14. Blake G.J., Ridker P.M. Novel clinical markers of vascular wall inflammation. Circulation Research. 89:2001;763-771.
15. Bonora E., Formentini G., Calcaterra F., Marinin F., Muggeo M. Homeostasis model assessment of insulin resistance predicts cardiovascular disease in type 2 diabetes mellitus. Diabetes. 49(Suppl. 1):2000;A21.
16. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Bonadonna R.C., Muggeo M. Prevalence rates, additional clinical features and risk of atherosclerosis in subjects with isolated insulin resistance and in subjects with the plurimetabolic syndrome. Diabetes. 49(Suppl. 1):2000;A385.
17. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., Alberiche M., Bonadonna R.C., Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 47:1998;1643-1649.
18. Bouloumié A., Bauersachs J., Linz W., Scholkens B.A., Wiemer G., Fleming I., Busse R. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 30:1997;934-941.
19. Brodsky S.V., Morrishow A.M., Dharia N., Gross S.S., Goligorsky M.S. Glucose scavenging of nitric oxide. American Journal of Physiology. Renal Physiology. 280:2001;F480-F486.
20. Brunzell J., Cohen B.R., Kreider M., Biswas N., Rattner R.E., Freed M.I., Marcovina S. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes. 50(Suppl. 2):2001;A141.
21. Buchan K.W., Hassall D.G. PPAR agonists as direct modulators of the vessel wall in cardiovascular disease. Medicinal Research Reviews. 20:2000;350-366.
22. Burleigh M.C., Briggs A.D., Lendon C.L., Davies M.J., Born G.V., Richardson P.D. Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations. Atherosclerosis. 96:1992;71-81.
23. Burne M.J., Elghandour A., Haq M., Saba S.R., Norman J., Condon T., Bennett F., Rabb H. IL-1 and TNF independent pathways mediate ICAM-1/VCAM-1 up-regulation in ischemia reperfusion injury. Journal of Leukocyte Biology. 70:2001;192-198.
24. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation Research. 87:2000;840-844.
25. Carlsen S.M., Waage A., Grill V., Folling I. Metformin increases circulating tumour necrosis factor-alpha levels in non-obese non-diabetic patients with coronary heart disease. Cytokine. 10:1998;66-69.
26. Chait A., Brazg R.L., Tribble D.L., Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. American Journal of Medicine. 94:1993;350-356.
27. Chan J.C., Tomlinson B., Critchley J.A., Cockram C.S., Walden R.J. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 16:1993;1035-1038.
28. Charles M.A., Morange P., Eschwege E., Andre P., Vague P., Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 21:1998;1967-1972.
29. Chen Z., Ishibashi S., Perrey S., Osuga J., Gotoda T., Kitamine T., Tamura Y., Okazaki H., Yahagi N., Iizuka Y., Shionoiri F., Ohashi K., Harada K., Shimano H., Nagai R., Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arteriosclerosis, Thrombosis, and Vascular Biology. 21:2001;372-377.
30. Claudel T., Leibowitz M.D., Fievet C., Tailleux A., Wagner B., Repa J.J., Torpier G., Lobaccaro J.M., Paterniti J.R., Mangelsdorf D.J., Heyman R.A., Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;2610-2615.
31. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., Palinski W., Hsueh W.A., Law R.E. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 21:2001;365-371.
32. Cominacini L., Garbin U., Fratta P.A., Campagnola M., Davoli A., Foot E., Sighieri G., Sironi A.M., Lo C.V., Ferrannini E. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 47:1998;130-133.
33. Cominacini L., Garbin U., Pasini A.F., Davoli A., Campagnola M., Rigoni A., Tosetti L., Lo C.V. The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity. Cell Adhesion and Communications. 7:1999;223-231.
34. Cominacini L., Garbin U., Pastorino A.M., Campagnola M., Fratta P.A., Davoli A., Rigoni A., Lo C.V. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia. 40:1997;165-172.
35. Dandona P., Aljada A., Mohanty P., Ghanim H., Hamouda W., Assian E., Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates lkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? Journal of Clinical Endocrinology and Metabolism. 86:2001;3257-3265.
36. Delafontaine P. Growth factors and vascular smooth muscle cell growth responses. European Heart Journal. 19(Suppl. G):1998;G18-G22.
37. Després J.P., Lamarche B., Mauriège P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. New England Journal of Medicine. 334:1996;952-957.
38. Ding Y., Vaziri N.D., Coulson R., Kamanna V.S., Roh D.D. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. American Journal of Physiology. Endocrinology and Metabolism. 279:2000;E11-E17.
39. Dubey R.K., Zhang H.Y., Reddy S.R., Boegehold M.A., Kotchen T.A. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. American Journal of Physiology. 265:1993;R726-R732.
40. Eriksson P., Nilsson L., Karpe F., Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired in the impaired fibrinolysis of hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 18:1998;20-26.
41. Eschwege E., Richard J.L., Thibult N., Ducimetiere P., Warnet J.M., Claude J.R., Rosselin G.E. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Hormone and Metabolic Research, Supplement. 15:1985;41-46.
42. Fazio S., Babaev V.R., Murray A.B., Hasty A.H., Carter K.J., Gleaves L.A., Atkinson J.B., Linton M.F. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proceedings of the National Academy of Sciences of the United States of America. 94:1997;4647-4652.
43. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. Journal of the American Medical Association. 287:2002;356-359.
44. Freed M., Fuell D., Menci L., Heise M., Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia. 43(Suppl. 1):2000;A267.
45. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., Isles C., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., Shepherd J., Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 103:2001;357-362.
46. Frohnert B.I., Hui T.Y., Bernlohr D.A. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. Journal of Biological Chemistry. 274:1999;3970-3977.
47. Frostegard J., Wu R., Giscombe R., Holm G., Lefvert A.K., Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arteriosclerosis and Thrombosis. 12:1992;461-467.
48. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. Journal of Clinical Investigation. 94:1994;2493-2503.
49. Garg R., Kumbkarni Y., Aljada A., Mohanty P., Ghanim H., Hamouda W., Dandona P. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilation in obese subjects. Hypertension. 36:2000;430-435.
50. Ghanim H., Garg R., Aljada A., Mohanty P., Kumbkarni Y., Assian E., Hamouda W., Dandona P. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. Journal of Clinical Endocrinology and Metabolism. 86:2001;1306-1312.
51. Ghazzi M.N., Perez J.E., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., Whitcomb R.W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. 46:1997;433-439.
52. Ginsberg H., Plutzky J., Sobel B.E. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. Journal of Cardiovascular Risk. 6:1999;337-346.
53. Goetze S., Xi X.P., Kawano H., Gotlibowski T., Fleck E., Hsueh W.A., Law R.E. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. Journal of Cardiovascular Pharmacology. 33:1999;798-806.
54. Gorog P., Kovacs I.B. Inhibition of vascular smooth muscle cell migration by intact endothelium is nitric oxide-mediated: interference by oxidised low density lipoproteins. Journal of Vascular Research. 35:1998;165-169.
55. Gruden G., Gnudi L., Rodriguez V., Johnson B., Thomas S., Hartley B., Raij L., Viberti G.C. GLUT1 is upregulated in glomerular hypertension: possible role in the pathophysiology of diabetic glomerulopathy. Diabetologia. 44(Suppl. 1):2001;A77.
56. Haffner S., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitozone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684.
57. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine. 339:1998;229-234.
58. Haffner S.M., Mykkanen L., Festa A., Burke J.P., Stern M.P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 101:2000;975-980.
59. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., Blomback M., Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2:1987;3-9.
60. Han K.H., Quehenberger O. Ligands for peroxisome proliferator-activated receptor inhibit monocyte CCR2 expression stimulated by plasma lipoproteins. Trends in Cardiovascular Medicine. 10:2000;209-216.
61. Hattori Y., Akimoto K., Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochemical and Biophysical Research Communications. 273:2000;1144-1149.
62. Howard G., O'Leary D.H., Zaccaro D., Haffner S., Rewers M., Hamman R., Selby J.V., Saad M.F., Savage P., Bergman R. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation. 93:1996;1809-1817.
63. Hsueh W.A., Law R.E. Cardiovascular risk continuum: implications of insulin resistance and diabetes. American Journal of Medicine. 105:1998;4S-14S.
64. Ihara H., Urano T., Takada A., Loskutoff D.J. Induction of plasminogen activator inhibitor-1 (PAI-1) gene expression in adipocytes by thiazolidinediones. FASEB Journal. 15:2001;1233-1235.
65. Inoue M., Itoh H., Tanaka T., Chun T.H., Doi K., Fukunaga Y., Sawada N., Yamshita J., Masatsugu K., Saito T., Sakaguchi S., Sone M., Yamahara K., Yurugi T., Nakao K. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-γ Arteriosclerosis, Thrombosis, and Vascular Biology. 21:2001;560-566.
66. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:2001;683-689.
67. Jackson S.M., Parhami F., Xi X.P., Berliner J.A., Hsueh W.A., Law R.E., Demer L.L. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell infarction. Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1999;2094-2104.
68. Jiang C., Ting A.T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
69. Juhan-Vague I., Alessi M.C., Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetogia. 34:1991;457-462.
70. Kato K., Satoh H., Endo Y., Yamada D., Midorikawa S., Sato W., Mizuno K., Fujita T., Tsukamoto K., Watanabe T. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochemical and Biophysical Research Commununications. 258:1999;431-435.
71. Kintscher U., Goetze S., Wakino S., Kim S., Nagpal S., Chandraratna R.A., Graf K., Fleck E., Hsueh W.A., Law R.E. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. European Journal of Pharmacology. 401:2000;259-270.
72. Kirpichnikov D., Sowers J.R. Diabetes mellitus and diabetes-associated vascular disease. Trends in Endocrinology and Metabolism. 12:2001;225-230.
73. Kobayashi M. Effects of current therapeutic interventions on insulin resistance. Diabetes, Obesity and Metabolism. 1:1999;S32-S40.
74. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 86:2001;3452-3456.
75. Kotchen T.A., Zhang H.Y., Reddy S., Hoffmann R.G. Effect of pioglitazone on vascular reactivity in vivo and in vitro. American Journal of Physiology. 270:1996;R660-R666.
76. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effect of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 49:2000;633-639.
77. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., Hsueh W.A. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 101:2000;1311-1318.
78. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes and Metabolism Research Reviews. 18(Suppl. 2):2002;S23-S29.
79. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 86:2001;280-288.
80. Ledru F., Ducimetiere P., Battaglia S., Courbon D., Beverelli F., Guize L., Guermonprez J.L., Diebold B. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. Journal of the American College of Cardiology. 37:2001;1543-1550.
81. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. Journal of Clinical Investigation. 106:2000;523-531.
82. Li Y., Chen H., Tan J., Wang X., Liang H., Sun X. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease-indicator of endothelial dysfunction and reduced fibrinolytic capacity. European Journal of Clinical Investigation. 28:1998;1050-1054.
83. Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. American Journal of Cardiology. 86:2000;3J-9J.
84. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;1004-1010.
85. Lip G.Y., Blann A.D., Zarifis J., Beevers M., Lip P.L., Beevers D.G. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. Journal of Hypertension. 13:1995;1674-1678.
86. Loviscach M., Rehman N., Carter L., Mudaliar S., Mohadeen P., Ciaraldi T.P., Veerkamp J.H., Henry R.R. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia. 43:2000;304-311.
87. Luscher T.F., Tanner F.C., Tschudi M.R., Noll G. Endothelial dysfunction in coronary artery disease. Annual Review of Medicine. 44:1993;395-418.
88. Lyons T.J., Li W., Wells-Knecht M.C., Jokl R. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes. 43:1994;1090-1095.
89. Mach F., Schonbeck U., Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis. 137:1998;S89-S95. Suppl.
90. Marfella R., Nappo F., De Angelis L., Paolisso G., Tagliamonte M.R., Giugliano D. Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients. Diabetes Care. 23:2000;658-663.
91. Margaglione M., Di Minno G., Grandone E., Vecchione G., Celentano E., Cappucci G., Grilli M., Simone P., Panico S., Mancini M. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arteriosclerosis and Thrombosis. 14:1994;1741-1745.
92. Marx N., Bourcier T., Sukhova G.K., Libby P., Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1999;546-551.
93. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., Libby P., Plutzky J., Luster A.D. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. Journal of Immunology. 164:2000;6503-6508.
94. Marx N., Schonbeck U., Lazar M.A., Libby P., Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circulation Research. 83:1998;1097-1103.
95. Marx N., Sukhova G., Murphy C., Libby P., Plutzky J. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. American Journal of Pathology. 153:1998;17-23.
96. Marx N., Sukhova G.K., Collins T., Libby P., Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 99:1999;3125-3131.
97. Mather K.J., Verma S., Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology. 37:2001;1344-1350.
98. Matsumoto K., Hirano K., Nozaki S., Takamoto A., Nishida M., Nakagawa-Toyama Y., Janabi M.Y., Ohya T., Yamashita S., Matsuzawa Y. Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its implication in atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology. 20:2000;1027-1032.
99. Mattock M.B., Barnes D.J., Viberti G., Keen H., Burt D., Hughes J.M., Fitzgerald A.P., Sandhu B., Jackson P.G. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes. 47:1998;1786-1792.
100. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 83:1998;1818-1820.
101. phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect. Diabetes. 50(Suppl. 2):2001;A68.
102. Mohanty P., Hamouda W., Garg R., Aljada A., Ghanim H., Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. Journal of Clinical Endocrinology and Metabolism. 85:2000;2970-2973.
103. Moreno P.R., Murcia A.M., Palacios I.F., Leon M.N., Bernardi V.H., Fuster V., Fallon J.T. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 102:2000;2180-2184.
104. Murakami T., Mataki C., Nagao C., Umetani M., Wada Y., Ishii M., Tsutsumi S., Kohro T., Saiura A., Aburatani H., Hamakubo T., Kodama T. The gene expression profile of human umbilical vein endothelial cells stimulated by tumor necrosis factor alpha using DNA microarray analysis. Journal of Atherosclerosis and Thrombosis. 7:2000;39-44.
105. Murphy G.J., Holder J.C. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends in Pharmacological Sciences. 21:2000;469-474.
106. Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 16:1993;621-629.
107. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 93:1998;229-240.
108. Nakamura T., Ushiyama C., Shimada N., Hayashi K., Ebihara I., Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. Journal of Diabetes and its Complications. 14:2000;250-254.
109. Nakamura T., Ushiyama C., Suzuki S., Shimada N., Sekizuka K., Ebihara L., Koide H. Effect of troglitazone on urinary albumin excretin and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabetic Medicine. 18:2001;308-313.
110. Nakata A., Nakagawa Y., Nishida M., Nozaki S., Miyagawa J., Nakagawa T., Tamura R., Matsumoto K., Kameda-Takemura K., Yamashita S., Matsuzawa Y. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1999;1333-1339.
111. Nisoli E., Carruba M.O., Tonello C., Macor C., Federspil G., Vettor R. Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes. 49:2000;319-324.
112. Nozue T., Michishita I., Minagawa F., Genda A. Troglitazone directly increases HDL cholesterol levels. Diabetes Care. 22:1999;355-356.
113. Ogihara T., Rakugi H., Ikegami H., Mikami H., Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. American Journal of Hypertension. 8:1995;316-320.
114. Orie N.N., Zidek W., Tepel M. Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. American Journal of Hypertension. 12:1999;1169-1174.
115. Panza J.A., Quyyumi A.A., Brush J.E.J., Epstein S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. New England Journal of Medicine. 323:1990;22-27.
116. Perriello G., Misericordia P., Volpi E., Santucci A., Santucci C., Ferrannini E., Ventura M.M., Santeusanio F., Brunetti P., Bolli G.B. Acute antihyperglycemic mechanisms of metformin in NIDMM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 43:1994;920-928.
117. Peuler J.D., Phare M.P., Iannucci A.R., Hodorek M.J. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. American Journal of Hypertension. 9:1996;188-192.
118. Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. American Journal of Cardiology. 84:1999;15J-20J.
119. Porsch-Oezcueruemez M., Kunz D., Kloer H.U., Luley C. Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease. Journal of the American College of Cardiology. 34:1999;1995-2001.
120. Pueyo M.E., Gonzalez W., Nicoletti A., Savoie F., Arnal J.F., Michel J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arteriosclerosis, Thrombosis, and Vascular Biology. 20:2000;645-651.
121. Pyörälä K., Savolainen E., Kaukola S., Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Medica Scandinavica Supplementum. 701:1985;38-52.
122. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proceedings of the National Academy of Sciences of the United States of America. 84:1987;2995-2998.
123. Quinones M.J., Pampaloni M.H., Juarez B.E., Wang Y., Carmona G.C., Van Herle K., Saad M.F., Schelbert H.R., Hsueh W.A. Insulin resistance in healthy Mexican Americans is associated with coronary artery endothelial dysfunction. Diabetes. 49(Suppl. 1):2000;A146.
124. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
125. Robinson A.C., Burke J., Robinson S., Johnston D.G., Elkeles R.S. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 21:1998;701-705.
126. Rosenblatt S., Miskin B., Glazer N.B., Prince M.J., Robertson K.E. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coronary Artery Disease. 12:2001;413-423.
127. Ross R. Atherosclerosis-an inflammatory disease. New England Journal of Medicine. 340:1999;115-126.
128. Rubies-Prat J., Ordoinez-Llanos J., Martin S., Blanco-Vaca F., Molina L., Goday A., Pedro-Botet J. Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension. Clinical and Experimental Hypertension. 23:2001;489-500.
129. Ryysy L., Yki-Jarvinen H. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in E-selectin concentrations in type 2 diabetes. Diabetes Care. 24:2001;549-554.
130. Sakai M., Miyazaki A., Hakamata H., Sato Y., Matsumura T., Kobori S., Shichiri M., Horiuchi S. Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology. 16:1996;600-605.
131. Scheidegger K.J., Butler S., Witztum J.L. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. Journal of Biological Chemistry. 272:1997;21609-21615.
132. Shah P.K. Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiology in Review. 8:2000;31-39.
133. Shah P.K., Falk E., Badimon J.J., Fernandez-Ortiz A., Mailhac A., Villareal-Levy G., Fallon J.T., Regnstrom J., Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degarding metalloproteinases and implications for plaque rupture. Circulation. 92:1995;1565-1569.
134. Shimaya A., Kurosaki E., Shioduka K., Nakano R., Shibasaki M., Shikama H. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Hormone and Metabolic Research. 30:1998;543-548.
135. Silveira A. Postprandial triglycerides and blood coagulation. Experimental and Clinical Endocrinology and Diabetes. 109:2001;S527-S532.
136. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:1993;434-444.
137. Stewart M., Jones N.P., Kreider M., Cohen B., Freed M., Biswas N., Rattner R., Brunzell J. Combined effects of rosiglitazone and atorvastatin on the dyslipidemia associated with type 2 diabetes. Diabetologia. 44(Suppl. 1):2001;A222.
138. Stopeck A.T., Nicholson A.C., Mancini F.P., Hajjar D.P. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. Journal of Biological Chemistry. 268:1993;17489-17494.
139. Tack C.J., Smits P., Demacker P.N., Stalenhoef A.F. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 21:1998;796-799.
140. Tailor A., Granger D.N. Role of adhesion molecules in vascular regulation and damage. Current Hypertension Reports. 2:2000;78-83.
141. Tellez Gil L., Rosello A.M., Collado T.A., Moreno R.L., Antonio F.O. Modulation of soluble phases of endothelial/leukocyte adhesion molecule 1, intercellular adhesion molecule 1, and vascular cell adhesion molecular 1 with interleukin-1beta after experimental endotoxic challenge. Critical Care Medicine. 29:2001;776-781.
142. Temelkova-Kurktschiev T.S., Koehler C., Leonhardt W., Schaper F., Henkel E., Siegert G., Hanefeld M. Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors. Diabetes Care. 22:1999;333-338.
143. Testa R., Bonfigli A.R., Piantanelli L., Manfrini S., Testa I., Gregorio F. Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice. 33:1996;111-118.
144. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 98:1998;2241-2247.
145. Title L.M., Cummings P.M., Giddens K., Nassar B.A. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. Journal of the American College of Cardiology. 36:2000;2185-2191.
146. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
147. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:1998;854-865.
148. Valmadrid C.T., Klein R., Moss S.E., Klein B.E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Archives of Internal Medicine. 160:2000;1093-1100.
149. Vinik Al., Erbas T., Park T.S., Nolan R., Pittenger G.L. Platelet dysfunction in type 2 diabetes. Diabetes Care. 24:2001;1476-1485.
150. Watanabe T., Pakala R., Katagiri T., Benedict C.R. Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. Journal of Hypertension. 19:2001;1065-1073.
151. Watanabe Y., Sunayama S., Shimada K., Sawano M., Hoshi S., Iwama Y., Mokuno H., Daida H., Yamaguchi H. Troglitazone improves endothelial dysfunction in patients with insulin resistance. Journal of Atherosclerosis and Thrombosis. 7:2000;159-163.
152. Wiman B., Ljungberg B., Chmielewska J., Urden G., Blomback M., Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. Journal of Laboratory and Clinical Medicine. 105:1985;265-270.
153. Wojakowski W., Gminski J. Soluble ICAM-1, VCAM-1 and E-selectin in children from families with high risk of atherosclerosis. International Journal of Molecular Medicine. 7:2001;181-185.
154. Xin X., Yang S., Kowalski J., Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. Journal of Biological Chemistry. 274:1999;9116-9121.
155. Young P.W., Cawthorne M.A., Coyle P.J., Holder J.C., Holman G.D., Kozka I.J., Kirkham D.M., Lister C.A., Smith S.A. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes. 44:1995;1087-1092.
156. Yue T.T., Chen J., Bao W., Narayanan P.K., Bril A., Jiang W., Lysko P.G., Gu J.L., Boyce R., Zimmerman D.M., Hart T.K., Buckingham R.E., Ohlstein E.H. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 104:2001;2588-2594.
157. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolffenbuttel B.H., Zinman B. Ramipril and the development of diabetes. Journal of the American Medical Association. 286:2001;1882-1885.
158. Zaman A.G., Helft G., Worthley S.G., Badimon J.J. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 149:2000;251-266.
159. Ziouzenkova O., Perrey S., Marx N., Bacqueville D., Plutzky A.J. Peroxisome proliferator-activated receptors. Current Atherosclerosis Reports. 4:2002;59-64.